Development

NorthStar's
Manufacturing

Within two years, we anticipate having dual U.S. operations used to produce, process and ship Mo-99 and other diagnostic and therapeutic radioisotopes products in our pipeline.

University of Missouri
Research Reactor (MURR®)

We currently produce cMo-99 in partnership with MURR®.

Image courtesy of MURR®

NorthStar Columbia Operations
Columbia, Missouri

NorthStar Columbia Operations’ processing and logistics center will continue to commercialize cMo-99.

NORTHSTAR BELOIT OPERATIONS,
BELOIT, WISCONSIN

In Beloit, we manufacture RadioGenix® Systems and their associated consumables and recycle cMo-99 source vessels. NorthStar’s Beloit Operations will also incorporate a state-of-the-art Isotope Processing facility to fill, package and ship cMo-99 produced at MURR® and an Accelerator Production facility to produce and distribute aMo-99. This second U.S. processing center will allow NorthStar to substantially increase output of Mo-99, ensuring a dependable domestic supply.

OUR ADVANCED ELECTRON-BEAM
ACCELERATORS ARE MAJOR
INVESTMENTS INTO A

GREEN
FUTURE

In addition, NorthStar has invested in innovative, environmentally friendly electron-beam accelerators, which are being installed in dedicated facilities on the Beloit campus. Here, Mo-100 will be converted to medically useful Mo-99 using a neutron knock-out method.

The first pair of Rhodotron® TT300 HE electron- beam accelerators are installed in the first of four accelerator facilities, with the first commercial product expected in 2023.

INNOVATING THE FUTURE OF THE

RADIOGENIX® SYSTEM
(technetium Tc 99m generator)

We continue to make seamless improvements to the RadioGenix System, based on important customer feedback. These enhancements are designed to maximize efficiency, provide new groundbreaking features and simplify radiopharmacy workflow even further.